X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (39) 39
index medicus (38) 38
humans (37) 37
female (36) 36
male (36) 36
aged (34) 34
chemotherapy (34) 34
middle aged (33) 33
cancer (28) 28
adult (22) 22
treatment outcome (17) 17
metastasis (16) 16
colorectal cancer (15) 15
stomach neoplasms - drug therapy (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
patients (13) 13
aged, 80 and over (12) 12
cancer therapies (12) 12
cisplatin (12) 12
clinical trials (12) 12
gastric cancer (12) 12
medicine & public health (12) 12
research (12) 12
care and treatment (11) 11
drug combinations (11) 11
pharmacology & pharmacy (11) 11
survival (11) 11
trial (11) 11
tumors (11) 11
antimitotic agents (10) 10
antineoplastic agents (10) 10
colorectal neoplasms - drug therapy (10) 10
stomach cancer (10) 10
adenocarcinoma (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
cancer research (9) 9
esophagus (9) 9
fluorouracil (9) 9
oxaliplatin (9) 9
solid tumors (9) 9
adenocarcinoma - drug therapy (8) 8
disease-free survival (8) 8
esophageal cancer (8) 8
fluorouracil - administration & dosage (8) 8
hematology, oncology and palliative medicine (8) 8
leucovorin (8) 8
pharmacology/toxicology (8) 8
stomach neoplasms - pathology (8) 8
therapy (8) 8
5-fluorouracil (7) 7
bevacizumab (7) 7
cisplatin - administration & dosage (7) 7
double-blind (7) 7
expression (7) 7
kaplan-meier estimate (7) 7
mutation (7) 7
neoplasm staging (7) 7
oncology, experimental (7) 7
original (7) 7
studies (7) 7
survival rate (7) 7
adenocarcinoma - mortality (6) 6
analysis (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
carcinoma (6) 6
drug therapy (6) 6
ligands (6) 6
medical research (6) 6
neutropenia (6) 6
original article (6) 6
oxonic acid - administration & dosage (6) 6
phase-iii (6) 6
platinum (6) 6
stomach neoplasms - mortality (6) 6
tegafur - administration & dosage (6) 6
toxicity (6) 6
1st-line therapy (5) 5
antibodies (5) 5
cancer patients (5) 5
cetuximab (5) 5
colorectal neoplasms - pathology (5) 5
complications and side effects (5) 5
digestive system diseases (5) 5
esophageal neoplasms - drug therapy (5) 5
follow-up studies (5) 5
irinotecan (5) 5
japan (5) 5
leucovorin - administration & dosage (5) 5
medical colleges (5) 5
medicine, experimental (5) 5
metastases (5) 5
monoclonal antibodies (5) 5
monotherapy (5) 5
multicenter (5) 5
oxonic acid - adverse effects (5) 5
pharmacokinetics (5) 5
prognosis (5) 5
retrospective studies (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 717 - 726
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 631 - 639
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 13, pp. 1278 - 1286
Journal Article
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 3, pp. 684 - 690
Purpose In this Phase II study, we evaluated the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin (CDDP) and 5-fluorouracil (5-FU) for Stage... 
Radiology | Hematology, Oncology and Palliative Medicine | Esophageal squamous cell carcinoma | Long-term toxicity | Salvage surgery | Chemoradiotherapy | SURGERY | SURVIVAL | THORACIC ESOPHAGUS | CANCER | CHEMOTHERAPY | SALVAGE ESOPHAGECTOMY | RADIATION-THERAPY | ONCOLOGY | CHEMORADIATION | RADIOTHERAPY | DEFINITIVE CHEMORADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Chemoradiotherapy - adverse effects | Age Factors | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Carcinoma, Squamous Cell - mortality | Fluorouracil - administration & dosage | Esophageal Neoplasms - mortality | Adult | Female | Surveys and Questionnaires | Esophageal Neoplasms - therapy | Radiotherapy Dosage | Chemoradiotherapy - methods | Drug Administration Schedule | Carcinoma, Squamous Cell - therapy | Survival Rate | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Health Status | Neoplasm Staging | Salvage Therapy - methods | Preoperative Care - methods | Medical colleges | Chemotherapy | Squamous cell carcinoma | Information services | Clinical trials | Esophageal cancer | Information services industry | Cisplatin | Cancer | Fluorouracil | Index Medicus | ESOPHAGUS | DIGESTIVE SYSTEM | COMPLEXES | HETEROCYCLIC COMPOUNDS | DEATH | INFUSION | MEDICINE | AZINES | ANTIMETABOLITES | FLUOROURACILS | IRRADIATION | ORGANIC HALOGEN COMPOUNDS | HYDROXY COMPOUNDS | THERAPY | DRUGS | RADIOLOGY AND NUCLEAR MEDICINE | PNEUMONITIS | ORGANIC NITROGEN COMPOUNDS | COMBINED THERAPY | RADIOLOGY | URACILS | NEOPLASMS | ORGANIC COMPOUNDS | ORGANIC FLUORINE COMPOUNDS | INTAKE | PYRIMIDINES | TOXICITY | SYMPTOMS | TRANSITION ELEMENT COMPLEXES | PLATINUM COMPLEXES | NUCLEAR MEDICINE | ORGANS | SURVIVAL TIME | DISEASES | CARCINOMAS | NAUSEA | BODY
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
Cancer Science, ISSN 1347-9032, 10/2015, Volume 106, Issue 10, pp. 1414 - 1420
We carried out a phase I/II trial of chemoradiotherapy concurrent with S‐1 and cisplatin to determine the maximum tolerated dose and recommended dose and to... 
S‐1 | stage II/III | cisplatin | esophageal carcinoma | Chemoradiotherapy | Esophageal carcinoma | Stage II/III | S-1 |